Advancing knowledge of human development, developmental disabilities, and neurodegenerative diseases.
Carl Ross has been selected to serve as managing director of Waisman Biomanufacturing. His appointment started July 1, following more than a year as its interim director. Located at the University of Wisconsin–Madison Waisman Center, the primary mission of Waisman Biomanufacturing is to help UW scientists and others efficiently translate scientific discoveries into early-stage clinical …
February 23, 2016 Waisman Biomanufacturing and Agilis Biotherapeutics, LLC, recently announced an exclusive partnership agreement for the production AGIL-FA, a novel gene therapy product for the treatment of Friedreich’s ataxia (FA). FA is an inherited neuromuscular disorder caused by a defect or mutation in the FXN gene. It is the most common inherited ataxia, with …
Introduction Recognizing the emerging field of therapeutic cell-based treatments for a growing number of diseases, including the field of regenerative medicine, the National Heart, Lung, and Blood Institute (NHLBI) held a workshop in 2002, where experts in cellular product manufacturing and clinical trial design came together to discuss the state of the cellular therapy field …
A spinoff business launched by a University of Wisconsin-Madison cancer researcher is attempting to harness the human immune system to fight prostate cancer.
David Tenenbaum – University Communications Developing a new drug takes enormous amounts of time, money and skill, but the bar is even higher for a promising stem-cell therapy. Many types of cells derived from these ultra-flexible parent cells are moving toward the market, but the very quality that makes stem cells so valuable also makes …
The grant will fund development work that will focus on the efficacy of a genetically modified living human skin substitute called ExpressGraftEnhance tissue in the prevention and disruption of biofilms. A biofilm is a community of bacteria growing in a matrix that adheres to a surface.
The long struggle to move the most versatile stem cells from the laboratory to the clinic got another boost with an $8.8 million contract award to the Waisman Clinical Biomanufacturing Facility at the University of Wisconsin-Madison.
WiCell Research Institute and Waisman Clinical Biomanufacturing Facility offer new stem cell banks to support translational research through clinical applications The WiCell™ Research Institute and the Waisman Clinical Biomanufacturing Facility (WCBF) announced today the release of the first current Good Manufacturing Practices (cGMP) feeder-independent pluripotent stem cell banks available for sale and distribution to …
Some of Madison’s most precious assets are deep-frozen in vials at University Research Park. The National Stem Cell Bank, the country’s only official repository of human embryonic stem cells, is housed at the WiCell Research Institute, a nonprofit organization affiliated with UW-Madison.
Two years after the National Institutes of Health created the National Stem Cell Bank, managers say the bank is starting to fulfill its mission: gathering the cells in one place, controlling their quality and shipping them to scientists at low cost.
